Post-Operative Use of Dopamine Agonist in Management of Remaining Nonfunctioning Pituitary Adenoma

AHMED ADEL AYAD, M.D.
The Department of Neurosurgery, Faculty of Medicine, Al Azhar University

Abstract

Background: Complete tumor elimination via transsphenoidal surgical operation is frequently hard for large non-functioning pituitary adenomas (NFPAs). A confirmed medical treating might be beneficial for their managing.

Aim of Study: To investigate the effectiveness of dopamine agonist medication in decreasing or avoiding the re-growing of NFPA after ward surgical operation.

Patients and Methods: This was a prospective, randomized, clinical trial done in Al-Azhar University Hospitals was conducted on 20 patients experienced primary transsphenoidal surgical operation for pituitary adenoma management, the study was carried out through a period of 12 months from March 2020 to March 2021.

Results: Tumour reduction rate of remaining cancer mass was significantly higher in medically-treated group, while tumour growing rate of remaining tumour mass was significantly elevated in controls.

Conclusion: Cabergoline (dopamine agonist was an effective medication for the treatment of remaining NFPA, and its usage was accompanying with an elevated tumour shrink-agates.

Key Words: Dopamine Agonists (DA) – Non-Functioning Pituitary Adenoma (NFPA).

Introduction

NFPAS are between the commonest tumours of the sellar area and are characterised by the non-attendance of clinical or bio-chemical proof of tumour-connected hormone rise [1].

These adenomas are normally big at diagnosing, and signs secondary to mass influences are mutual; those involve complications, visible disorders, and hypopituitarism [2-4]. Most adenomas are capable of synthesize gonadotropins but don’t secrete them. [2].

Transsphenoidal operative resections are the 1st-line treatment for NFPA. But, entire elimination of extremely big tumours may be hard, and those adenomas give an elevated rate of remaining tumour [3]. In those remaining tumours, radio-therapy is a powerful treatment option, with >90% tumour controlling over 10-yrs [4]. But, this elevated efficacy is balanced by an elevated occurrence of complications like hypo-pituitarism, cognitive impairment, and danger of strokes [5].

Stereotactic mode is taken into consideration to be more-safe, however the occurrence of hypopituitarism was 72% over 10-yrs, identical to that of traditional radio-therapy. For those causes, radio-therapy isn't completely endorsed for the treating the remaining NFPA [6].

Alternative option is medical observation; however, the occurrence of relapse is extremely elevated (67.9% over 15-yrs), and an increased standardized death ratio of 1.65 was described [2,7].

NFPA comprises the commonest shape of pituitary macro-adenomas that needoperative interventions, but they stay the only pituitary tumour subtype for which no medications are powerful. This contrasts with powerful medications existing for the management of hormone-secreting pituitary tumours [8].

The majority of NFPAs express dopamine receptors, mainly dopamine receptors-2 (D2R). Consequently, DA reduces gonadotropin secretions and constrain thymidine combination in vitro, giving a possible treatment goal for NFPA [9].

But, dopaminergic bonding locations in addition to D2R mRNA isoforms are lesser amount in NFPA in comparison to in prolactinomas, possibly in accordance to the modest rate of tumour reduction-accomplished by DAs [10]. Small reports suggested
that DA might retard NFPA growing. [11,12,13] however to date, this possible treatment modality hasn’t been widely experienced [14].

The present study aimed to investigate the effectiveness of dopamine agonist medication in decreasing or avoiding the re-growing of nonfunctioning pituitary adenoma NFPA after ward surgical operation.

**Material and Methods**

This was a prospective, randomized, clinical trial done in Al-Azhar University Hospitals was conducted on 20 patients experienced primary transsphenoidal surgical operation for pituitary adenoma management, the study was carried out through a period of 6 months from October 2020 to May 2021.

Eligible adults (>18 years of age) who have a remaining tumour masses detected by MRI 6-mths (+/-1 mo) after ward operation. Exclusion criteria involved silent corticotroph and silent somatotroph tumours, and preceding history of radiotherapy.

Informed written agreement was attained from each case to be involved in this work.

The NFPA diagnosing was founded in the subsequent criteria: (1) Detections of a pituitary tumour via MRI, with or not local tumour symptoms including headaches and visible acuity/field defect; (2) Non attendance of the medical features of hyper-secretion of frontal pituitary hormone; (3) Attendance of ordinary or small circulating growing hormones (GH), insulin-like growing factors 1 (IGF-1), thyroid-stimulation hormones (TSH), thyroid hormones, adrenocorticotropic hormones (ACTH), or 24-hour urinary cortisol level; and (4) Post-surgical histo-pathologic examinations showing pituitary adenoma. Cases with increased prolactin (PRL; max 50ng/dL) with no medical symptoms of hyper-prolactinemia had been involved. Immuno-histo-chemistry (IHC) for frontal pituitary hormones was achieved in all specimen tumours.

Contributors had been randomized then grouped to the clinical-treatment group (cabergoline) or the controls (medical observations) in a 1:1 ratio. We employed a simple randomizing technique in line with the cases’ time of arrival.

a- Medically-treated group: In an open-label way, cabergoline was started at 0.5mg 3 doses every week up to every day dosage of 0.5mg. In all patients, the goal dosage of 3.5mg per week was accomplished throughout 15-days and preserved till termination of the present work. Cabergoline was distributed for a cycle of 30-days, and the cases had to go back an empty bundle to get a new one. As a protection precaution, researchers can be called by telephone at any instance in situation cases had to told negative events. An echo-cardiogram has been carried out earlier and throughout following-up.

b- Control group: Cases had been exposed to a wait-and-see method with no medical treatments. All people had been assessed at 6 and 12-mths.

**Tumoursize Assessment via MRI:**

MRI images had been done with gadolinium contrast and assessed via qualified neuro-radiologists at all institutions. Maximal tumour diameter in every plane had been employed for MRI images comparing. Matching had been done with the latest images, and as well with antecedent existing images. A variation in tumour volume was taken into consideration as large and recorded as if a distinction of at minimum diameter of 0.2cm was found.

Cases experienced pituitary characteristic and neuro-ophthalmological evaluation involving visible field earlier than and 4-6-wks afterward surgical operation. At every visit, essential symptoms and bodily circumstance had been evaluated, and reassessment of pituitary feature and vision had been done as per standard medical procedure. Pituitary hormone shortages had been managed with hormone substitution treatment, excluding for growing hormone shortage that wasn’t repeatedly assessed or managed.

**Immuno-histo-chemistry (IHC):**

Immuno-staining for complete pituitary hormones expressing and Ki-67 proliferating index was done in the particular medical pathology labs. D2R and estrogen receptors [ER **a** (ESR1)] and **ERp** (ESR2) had been immuno-stained, digitalized, and counted on the Cedars-Sinai Translational Research Core in 53 tumour specimens of DA-managed cases. The percent of positive cells and staining intensities was recorded for all slides via the immuno-reactivity score system (IRS) [15] and the (QUICK-Score) method [19].

**Statistical analysis:**

Data analysis had been performed via windows-based IBM-SPSS-22 for windows. Data had been tested for normal distributions via the Shapiro Walk testing. Qualitative data had been introduced in the form of frequency and relative percent. Chi square testing (X^2) and Fisher precise was employed to estimate distinction between qualitative variables as showed. Quantitative data had been introduced
as mean ± SD (Standard deviation) for parametric and medians and ranges for non parametric data. Non-dependent t-testing was employed to estimate distinction between quantitative variables. Kaplan-Meier technique used to estimate event free survival and log rank testing in comparison to survival curves (p-value was taken into consideration to be significant at ≤ 0.05 level). All statistical evaluations had been tailed with significance Level of p-value ≤ 0.05 shows significant, <0.05 shows Non-significant change.

**Results**

### Table (1): Demographic data.

<table>
<thead>
<tr>
<th></th>
<th>Medically-treated (n=10)</th>
<th>Control (n=10)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (yrs):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>52.98±3.75</td>
<td>49.34±4.94</td>
<td>.079</td>
</tr>
<tr>
<td><strong>BMI (kg/m²):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>27.42±3.67</td>
<td>25.64±4.86</td>
<td>.368</td>
</tr>
<tr>
<td><strong>Prolactin (µg/l):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>25.43±2.37</td>
<td>26.58±2.59</td>
<td>.894</td>
</tr>
<tr>
<td><strong>Sex:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7 70</td>
<td>5 50</td>
<td>.361</td>
</tr>
<tr>
<td>Female</td>
<td>3 30</td>
<td>5 50</td>
<td></td>
</tr>
</tbody>
</table>

Regrading demographic, no significance found between the groups.

### Table (2): Anatomical features of remaining tumour mass.

<table>
<thead>
<tr>
<th></th>
<th>Medically-treated (n=10)</th>
<th>Control (n=10)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>0 1</td>
<td>1 10</td>
<td>.572</td>
</tr>
<tr>
<td>II</td>
<td>3 30</td>
<td>3 30</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>1 10</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>6 60</td>
<td>6 60</td>
<td></td>
</tr>
<tr>
<td><strong>Supra:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4 40</td>
<td>4 40</td>
<td>.774</td>
</tr>
<tr>
<td>A</td>
<td>4 40</td>
<td>5 50</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>1 10</td>
<td>1 10</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>1 10</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Infra:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4 40</td>
<td>5 50</td>
<td>.931</td>
</tr>
<tr>
<td>A</td>
<td>2 20</td>
<td>1 10</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>3 30</td>
<td>3 30</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>1 10</td>
<td>1 10</td>
<td></td>
</tr>
<tr>
<td><strong>Cavernous:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>5 50</td>
<td>6 60</td>
<td>.653</td>
</tr>
<tr>
<td>E</td>
<td>5 50</td>
<td>4 40</td>
<td></td>
</tr>
</tbody>
</table>

Grade-I, II, III and IV show micro-adenoma, non-invasive macro-adenoma, invasive micro-adenoma and invasive macro-adenoma, respectively. Stages A, B and C show growing degree of supra-sellar extensions. Stages a, b and c show-growing degree of infra-sellar extension. Stage E specifies cavernous sinus invasions. 0 shows absent extra-sellar extension. Non significant was existing among the groups.

**Immunostaining pattern results:**

Positive immuno-staining for FSH and LH was noticed in 60% of tumours from the controls and in 60% of tumours in the medically-treated group. There were 20% and 30% null tumours in the controls and medically-treated group, respectively. Prolactin staining in a few cells was found in 10% of tumours from the controls and in none from the medically-treated group. No association was found among tumour staining features and tumour growing throughout following-up.

### Table (3): Remaining tumour mass response.

<table>
<thead>
<tr>
<th></th>
<th>Medically-treated (n=10)</th>
<th>Control (n=10)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stable</strong></td>
<td>5 50</td>
<td>3 30</td>
<td>.011</td>
</tr>
<tr>
<td><strong>Reduction</strong></td>
<td>4 40</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Growing</strong></td>
<td>1 20</td>
<td>7 70</td>
<td></td>
</tr>
</tbody>
</table>

Tumour reduction rate of remaining tumour mass was significantly higher in medically-treated group, while tumour growing rate of remaining tumour mass was significantly higher in control group.

**Growth free survival**

![Fig. (1): Tumour growing free survival in cases with post-operative remaining tumour in accordance to therapy group (p=0.011). Tumour growing-free survival at 2-yrs was 60%, respectively in the controls. Tumour growing-free survival at 2-yrs was 90% in medically-treated group.](image-url)
Discussion

Clinically NFPAs are the commonest pituitary tumours after ward prolactinomas. The nonattendance of clinical signs and symptoms of hormonal hyper-secretion may make a contribution to the overdue of the disorder diagnosing. Thus, the mainstream of cases are looking for clinical attentions for symptoms due to mass impact, like: Neuro-ophthalmologic signs and hypo-pituitarism. Other arrangements involve pituitary apoplexy or arelated result on scanning investigations. Mass impact and hypopituitarism cause elevated morbidity and death. But early diagnosing and powerful therapy reduces morbidity and death [17].

Surgical operation is taken into consideration as the primary choice in NFPA managing. But remaining mass is a mutual post-operative result in the majority of these cases because of the reality that the diagnosing is commonly postponed and the tumour reaching a big volume with suprasellar and parasellar extensions [18].

NFPA is a difficult tumour. It is commonly reached to a big volume earlier to its clinical manifestations. Surgical treatment is the primary choice in treating a big NFPA leading to compressing manifestation but with common post-operative remaining masses this is commonly required extra management. Post-operative radio-therapy carried common side results which open the door for post-operative clinical management with dopamine agonist (DA) medications built at the reality that those tumours have a variable amounts of dopamine receptors. Deficiency of randomized, placebo-controlled trials avoids any conclusions on the efficiency of these medications. Its function in controlling post-operative proliferations and reducing the NFPA recurrence rate remains uncertain [19].

The current work aimed to evaluate the efficiency of dopamine agonist medications to reduce or prevent the re-growing of NFPA after ward surgical operation.

This was a prospective, randomized; clinical study that was performed on 20 cases experienced primary trans sphenoidal surgical operation for pituitary adenoma management. Contributors were randomized and grouped to the medically-treated group (cabergoline) and matching controls (clinical observations).

In the current study, we found that mean ± SD of age was 52.98±3.75 years in medical therapy group, and was 49.34±4.94 years in controls, and there were non significant changes among the studied groups regarding ages, BMI, Gender and prolactin levels.
In agreement with our findings, the study of Mahmoud et al., [19] reported that 32-cases were involved in this work. 21-cases (66%) were women and 11-cases (34%) were men. Their age ranging between 18 and 65-yrs with age mean of 37-yrs.

Another study of Batista et al., [20] reported that the analyzed subjects had mean ± SD of age was 49.8± 11.8-yrs in medical therapy group, and was 50.0± 12.2-yrs in controls, and non significant changes were found among the studied groups regarding ages and gender, and 56.0% were females. All cases harbored macro-adenomas earlier to surgical operation.

Post-surgical surveillance of NFPA is founded on MRI at 3 or 6-mths then afterward 1-yr. When no adenomatous remainder was existing, yearly surveillance is suggested for 5-yrs and then at 7, 10 and 15-yrs. In situation of remainder or unsure MRI, extended yearly surveillance monitor any progressions. Reintervention is specified if full-remainder re-section is possible, or for symptomatic optic path-ways compressions, to make a safety border amid the tumour and the optic path-ways. In the current work, we found that tumour growing rate of remaining tumour mass was significantly higher in medically-treated group, while tumour growing rate of remaining tumour mass was significantly higher in control group.

In the study on our hands, Positive immunostaining for FSH and LH was founded in 60% of tumours from the controls and in 60% of tumours in the medically-treated group. There were 20% and 30% null tumours in the controls and medically-treated groups, respectively. Prolactin staining in a few cells was found in 10% of tumours from the controls and in none from the medically-treated group. There was no association among tumour staining features and tumour growing throughout follow-up.

In comparison with the study of Batista et al., [20] which reported that the mean Ki-67 labeling index was 0.8 (0.2 to 1.2). In all, 71 of 80 (88.7%) cases expressed D2R with predominantly cytoplasmic staining and an H-scoring median of 188.0 (120.0 to 300.0), and 18 of 80 (22.5%) patientshowed nuclei stained positively for ER with a median H-scoring of 0.0 (0.0 to 10.0). Nonsignificant change was found in IHC tumour phenotypes among the studied groups.

Subsequently the identification of dopaminergic receptor in NFPA, pharma-cological management of NFPA was taken into consideration as a substitute to radio-therapy or surgical operation. Up to now, the medical usage of DAs in NFPA cases was assessed in some reports.16-18 But, the majority of them current modest and inconclusive findings, and no medical treatment for NFPA was confirmed-to date (24;25).

In the current work, we found that tumour reduction rate of remaining tumour mass was significantly higher in medically-treated group, while tumour growing rate of remaining tumour mass was significantly higher in control group.

Batista et al., [20] concluded that tumour shrinkage can characteristically be found in the 1st-yr of cabergoline use (p-value=0.02), taking in to consideration that they found a very small number instances of overdue tumour shrinkage in their report. Similarly, considerable shrinkage in NFPA with quick intervals (6 mo) of cabergoline was formerly defined in small report of Vieira et al., [25] Altogether, those data suggest that a minimal duration of 6-mths may be employed for the estimation of responding to cabergoline for NFPA management assessment. But, the duration for cabergoline usage in remaining tumour hasn’t been expected yet, and medical research with extended following-up may be helpful to find it.
The most suitable medical report up to now assessing DA in NFPA management was lately published by Greenman et al., [26]. In that report, 55-cases with a remaining tumour (preventive group) and 24 cases with remaining tumour growing (remedial group) have been managed with cabergoline and in comparison, with controls of 60 NFPA cases. 19 Substantial tumour shrinkage and an enhanced progressing free survival have been located in the groups with DA usage. But, this report was not a clinical trial and had some essential restrictions, like no standardizations of DA medication and doses.

Also, Garcia et al., [27] was carried out on 19-cases (10 males and 9 females) followed on the University Hospital of Brasilia and harboring non-functioning pituitary macro-adenomas have been registered in the investigation. 11 cases have been formerly presented to trans-sphenoidal surgical operation, and in 8 cases no previous treatments were founded. Their responding to the usage of cabergoline (2mg/wk) for 6-mths was assessed. Substantial tumour reduction (above 25% from base-line tumour size) was found in 6 (31.6%) of the 19 cases, and no negative results have been found throughout management. In 9 cases (47.4%), a decrease in tumour size of a minimum 10% was noticed; while tumour growing was found in 4 cases (rise above 25 % was only found in a single case). Cabergoline (2mg/wk) may cause considerable tumour reduction in NFPA in a significant variety of cases, and this impact may be found early (6-mths after ward initial medications). Thus, this treatment approach can be a lower cost and secure opportunity for treatment of NFPA in cases with remnant or recurrent tumour after ward trans-sphenoidal surgical operation or in those not operated via contraindication or rejection to operative procedures.

In contrast, Dekkers et al., [28] said that unprompted decrease of tumour volume happened in 29% in their cases and therefore they recommend that just observations of some chosen patients of NFPA can be a choice for management supplied there are no compressive symptoms as visible influence or hypo-pituitarism.

Furthermore, in the current work, we determined that tumour growing free survival in cases with post-operative remaining tumour in accordance to treatment group (p=0.011). Tumour growing-free survival at 2-yrs was 60%, correspondingly in the controls. Tumour growing-free survival at 2-yrs was 90% in medically-treated group.

Our findings are in agreement with Batista et al., [20] said that the mean progresses-free survive was 23.2-mths [95% confidence range (CI), 22.3-24.1 ] in the medically-treated group, which was considerably elevated than the 20.8-mths (95% CI, 19.2-22.4) of the controls (p=0.01; Fig. 3B). The real 6-mths progressions-free survival was 96% and 94% for cases from the medically-treated and controls, correspondingly. The real 1-yr progressions-free survival for cases in the medically-treated group was 94%, in comparison with 78% in the controls.

In conclusion, cabergoline is a secure and powerful medication and appears to be a hopeful substituent to radio-therapy for the treatment of NFPA cases with remaining tumour. But, there’s no dependable clinical, laboratory, or immuno-histochemical marker to expect their responsiveness to cabergoline.

References


تقييم استخدام محفزات الدوبامين لعلاج المتبقية من أورام الغدة النخامية الغير نشطة بعد إجراء الجراحة

خليفة البحث: استئصال أورام الغدة النخامية غير العاملة كبريرة الحجم بواسطة المنظار الجراحي من الممكن أن يكون غير كافى لاستئصال الورم بالكامل ويتبقى بقايا الورم يتم الآن استخدام بعض التقنيات المفيدة لإدارة بقايا الورم المستقل مثل استخدام الأشعة والذى أثبت فاعلية بنسبة تصل إلى 90% إلا أن وجد له مضاعفات كعدد جديد وكتواف كسل للغدة النخامية.

ماما فتح المجال إلى دراسة تأثير محفزات الدوبامين وتأثيرها على بقايا الورم الحميد النخامي غير النشط.

الهدف من البحث: تقييم هذه الدراسة سلامة ودقة استخدام محفزات الدوبامين في إدارة الورم الحميد النخامي المتبقى غير النشط بعد إجراء الجراحة.

المريض وطريقة البحث: أجريت الجراحة على (20 مريض) تم إدخالهم إلى المستشفى لإجراء عمليات استئصال أورام الغدة النخامية بواسطة المنظار الجراحي وتم تقسيم المرضى إلى مجموعتين مجموعتين تستخدم محفزات الدوبامين سبيت مجموعة (أ) ومجموعة تستعمل لأشعاع وسبيت مجموعة (ب).

نتائج البحث: أظهرت النتائج مجموعتي (أ) تم استقرار بنسبة (65%) وتمثلت بقايا الورم الحميد النخامي بنسبة (40%) وتم إرجاع الورم بنسبة (15%).

أما بالنسبة لمجموعة (ب) تم استقرار باصد (20%) وتم تقلص الورم بنسبة (20%) وتم إرجاع الورم بنسبة (20%).

الاستنتاج: استخدام محفزات الدوبامين بعد الجراحة في إدارة الورم الحميد النخامي المتبقى غير النشط أكثر فاعلية وأماناً للمريض مقارنة باستخدام الأشعة وماله من أضرار جانبية على المريض.

Dopamine Agonist to Pituitary Adenoma